Invention Grant
- Patent Title: (+)-2-[1-(3-Ethoxy-4- methoxyphenyl)-2-methylsulfonylethyl]- 4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
-
Application No.: US17003238Application Date: 2020-08-26
-
Publication No.: US11260046B2Publication Date: 2022-03-01
- Inventor: George W. Muller , Peter H. Schafer , Hon-Wah Man , Chuansheng Ge
- Applicant: AMGEN INC.
- Applicant Address: US CA Thousand Oaks
- Assignee: AMGEN INC.
- Current Assignee: AMGEN INC.
- Current Assignee Address: US CA Thousand Oaks
- Agency: Marshall, Gerstein & Borun LLP
- Main IPC: C07C317/28
- IPC: C07C317/28 ; A61K31/4035 ; C07D209/48 ; A61K45/06
![(+)-2-[1-(3-Ethoxy-4- methoxyphenyl)-2-methylsulfonylethyl]- 4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof](/abs-image/US/2022/03/01/US11260046B2/abs.jpg.150x150.jpg)
Abstract:
Stereomerically pure (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, substantially free of its (−) isomer, and prodrugs, metabolites, polymorphs, salts, solvates, hydrates, and clathrates thereof are discussed. Also discussed are methods of using and pharmaceutical compositions comprising the (+) enantiomer of 2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione are disclosed. The methods include methods of treating and/or preventing disorders ameliorated by the reduction of levels of TNF-α or the inhibition of PDE4.
Public/Granted literature
Information query